Acquiring distressed diagnostics laboratory assets at significant discounts with proven infrastructure capable of 90,000+ samples per day processing capacity.
Flexible investment structures with strong asset coverage
Future lab acquisitions (Lab 1, Lab 2, etc.) can be funded through Phase 2 capital raise or seller equity participation as opportunities arise. Distressed lab owners often prefer equity in a larger platform over cash-only exits — preserving capital while aligning incentives.
A protected downside with significant upside through strategic lab consolidation
$22.6M in hard assets (building + equipment) backing $10M equity investment. Building worth $11.5M (7% cap, fully leased) with $3M instant equity on exercise. Equipment acquired at 45% discount to appraised OLV.
Platform assets previously processed 90,000 samples/day, generating $102M revenue and $36.4M EBITDA (36% margin). High-complexity CLIA certification positions for B2B reference lab services.
7,000+ independent labs in the U.S. with many distressed or aging owners seeking exits. Target acquisitions (Lab 1, Lab 2, etc.) at 0.3-0.5x revenue multiples with OnParo LIS integration creating immediate synergies.
Proven track record with clear exit path
World-class laboratory facility with comprehensive equipment suite
Greenville, South Carolina
Comprehensive suite including NovaSeq, Cobas, LC-MS/MS systems
Acquiring at ~45% discount to appraised OLV
Building + Equipment combined value
Hard asset protection on $10M equity investment
Phased approach to laboratory consolidation
Acquire BMD license and equipment ($6.1M), secure building ($8.5M total for $11.5M value), deploy OnParo LIS. Establishes 90K samples/day capacity and operational foundation.
Target distressed laboratories at 0.3-0.5x revenue. Acquisitions funded via Phase 2 capital raise OR seller equity participation. Focus: TX, AZ, NY, OH, FL, CA. Targets confidential until LOI.
Migrate acquired labs to OnParo LIS platform within 60-90 days. Centralize complex testing to platform lab. Realize operational synergies and margin improvement.
Leverage high-capacity infrastructure to offer PCR and NGS testing services to smaller labs. Low cost per test due to scale creates competitive advantage and recurring revenue.
Experienced operator with proven track record
Built Premier Medical to $100M+ revenue and $36M EBITDA. Deep expertise in diagnostic laboratory operations, Medicare billing, and healthcare technology. Founder of OnParo LIS. Scaled operations to 90,000 samples/day processing capacity.
Interested in learning more about this investment opportunity? Contact us to receive the complete DD package including financial models, asset appraisals, and strategy documentation.
Request DD Package